Diastolic Dysfunction as a Link Between Hypertension and Heart Failure

Medical Clinics of North America

Volumn 93, Issue 3, 2009, Pages 647-664

  Verma, Anil ^a   Solomon, Scott D ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Diastolic dysfunction; Diastolic heart failure; Heart failure; Heart failure with preserved ejection fraction; Hypertension; Left ventricular hypertrophy

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; CANDESARTAN; CHLORTALIDONE; COLLAGEN; COLLAGEN FIBRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; MCC 135; NEUROHORMONE; PERINDOPRIL; PLACEBO; RAMIPRIL; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VALSARTAN;

ADAPTATION; AGING; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; BLOOD PRESSURE REGULATION; CALCIUM ANTAGONISM; CALCIUM HOMEOSTASIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CORONARY ARTERY DISEASE; CYTOSKELETON; DIASTOLE; DIASTOLIC DYSFUNCTION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENDURANCE; EXERCISE; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; HEART ATRIUM ENLARGEMENT; HEART CATHETERIZATION; HEART CONTRACTION; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE COMPLIANCE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART MUSCLE RELAXATION; HEART PROTECTION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE COMPLIANCE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE REMODELING; HEMODYNAMICS; HOSPITALIZATION; HUMAN; HYPERTENSION; KINESIOTHERAPY; LIFESTYLE MODIFICATION; MORTALITY; NEUROENDOCRINOLOGY; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SEX DIFFERENCE; SODIUM INTAKE; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; SYSTOLE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; WALKING;

AGING; ENDOTHELIUM; EXTRACELLULAR MATRIX; HEART FAILURE, DIASTOLIC; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MUSCLE CELLS; STROKE VOLUME;

EID: 65449143206     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2009.02.013     Document Type: Review

References (87)

1. Redfiled M.M., Jacobsen S.J., Burnett Jr. J.C., et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289 (2003) 194-202
2. Yancy C.W., Lopatin M., Stevenson L.W., et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) database. J Am Coll Cardiol 47 (2006) 76-84
3. Owan T.E., Hodge D.O., Herges R.M., et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006) 251-259
4. Redfiled Steven J., Jacobsen, Borlaug B.A., et al. Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation 112 (2005) 2254-2262
5. Bella J.N., Palmieri V., Roman M.J., et al. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the strong heart study. Circulation 105 (2002) 1928-1933
6. Chinnaiyan K.M., Alexander D., Maddens M., et al. Curriculum in cardiology: integrated diagnosis and management of diastolic heart failure. Am Heart J 153 (2007) 189-200
7. Bhatia R.S., Tu J.V., Lee D.S., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 (2006) 260-269
8. Solomon S.D., Anavekar N., Skali H., et al., Candesartan in Heart Failure Reduction in Mortality (CHARM) Investigators [2005]. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 112 (2005) 3738-3744
9. Morgan J.P. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. N Engl J Med 325 9 (1991) 625-632
10. Slama M., Susic D., Varagic J., et al. Diastolic dysfunction in hypertension. Curr Opin Cardiol 17 (2002) 368-373
11. Zile M., and Brutsaert D. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 105 (2002) 1387-1393
12. Tian R., Nascimben L., Ingwall J.S., et al. Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts. Circulation 96 (1997) 1313-1319
13. Garcia M. Left ventricular filling. Heart Fail Clin 4 (2008) 47-56
14. Desai A. Current understanding of heart failure with preserved ejection fraction. Curr Opin Cardiol 22 (2007) 578-585
15. Solomon S.D., Janardhanan R., Verma A., et al. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 369 (2007) 2079-2087
16. Aeschbacher B.C., Hutter D., Fuhrer J., et al. Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension. Am J Hypertens 14 (2001) 106-113
17. Chobanian A.V., Bakris G.L., Black H.R., et al., and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42 (2003) 1206-1252
18. Izzo Jr. J.L., Levy D., and Black H.R. Clinical advisory statement. Importance of systolic blood pressure in older Americans. Hypertension 35 (2000) 1021-1024
19. Susic D., and Frohlich E.D. The aging hypertensive heart: a brief update. Nat Clin Pract Cardiovasc Med 5 2 (2008) 104-110
20. Gates P.E., Tanaka H., Hiatt W.R., et al. Dietary sodium restriction rapidly improves large elastic artery compliance in older adults with systolic hypertension. Hypertension 44 (2004) 35-41
21. O'Rourke M. Arterial stiffness, systolic blood pressure, and logical treatment of arterial hypertension. Hypertension 15 (1990) 339-347
22. Ouzounian M., Lee D.S., and Liu P. Diastolic heart failure: mechanism and controversies. Nat Clin Pract Cardiovasc Med 5 7 (2008) 375-386
23. Bronzwaer J.G., and Paulus W.J. Matrix, cytoskeleton, or myofilaments: which one to blame for diastolic left ventricular dysfunction?. Prog Cardiovasc Dis 47 4 (2005) 276-284
24. Norton G.R., Tsotetsi J., Trifunovic B., et al. Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation 96 6 (1997) 1991-1998
25. Weber K.T., and Brilla C.G. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 83 (1991) 1849-1865
26. Zile M.R., and Brutsaert D.L. New concepts in diastolic dysfunction and diastolic heart failure: part II: causal mechanisms and treatment. Circulation 105 (2002) 1503-1508
27. Weber K.T. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13 (1989) 1637-1652
28. Spinale F.S., Coker M.L., Bond B.R., et al. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Cardiovasc Res 46 (2000) 225-238
29. Susic D., Varagic J., Ahn J., et al. Crosslink breakers: a new approach to cardiovascular therapy. Curr Opin Cardiol 19 (2004) 336-340
30. Zhao W., Choi J.H., Hong G., et al. Left ventricular relaxation. Heart Fail Clin 4 (2008) 37-46
31. Cain B.S., Meldrum D.R., Joo K.S., et al. Human SERCA2a levels correlate inversely with age in senescent human myocardium. J Am Coll Cardiol 32 (1998) 458-467
32. Flesch M., Schiffer F., Zolk O., et al. Contractile systolic and diastolic dysfunction in renin-induced hypertensive cardiomyopathy. Hypertension 30 (1997) 383-391
33. Cooper IV G. Cardiocyte cytoskeleton in hypertrophied myocardium. Heart Fail Rev 5 (2000) 187-201
34. Tagawa H., Wang N., Narishige T., et al. Cytoskeletal mechanics in pressure overload cardiac hypertrophy. Circ Res 80 (1997) 281-289
35. Zile M.R., Green G.R., Schuyler G.T., et al. Cardiocyte cytoskeleton in patients with left ventricular pressure overload hypertrophy. J Am Coll Cardiol 37 4 (2001) 1080-1084
36. Borbely A., van der Velden J., Papp Z., et al. Cardiomyocyte stiffness in diastolic heart failure. Circulation 111 (2005) 774-781
37. van Heerebeek L., Borbély A., Nissen H.W.M., et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 113 (2006) 1966-1973
38. Brutsaert D.L., Fransen P., Andries L.J., et al. Cardiac endothelium and myocardial function. Cardiovasc Res 38 (1998) 281-290
39. Taddei S., Virdis A., Ghiadoni L., et al. Endothelium, aging, and hypertension. Curr Hypertens Rep 8 (2006) 84-89
40. Struthers A.D. Aldosterone blockade in cardiovascular disease. Heart 90 (2004) 1229-1234
41. Hahn A.W., Resink T.J., Scott Burden T., et al. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul 1 (1990) 649-659
42. Mottram P.M., Haluska B., Leano R., et al. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110 (2004) 558-565
43. Levy D., Savage D.D., Garrison R.J., et al. Echocardiographic criteria for left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol 59 (1987) 956-960
44. Levy D., Garrison R.J., Savage D.D., et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 (1990) 1561-1566
45. Hill J.A., and Olson E. Cardiac plasticity. N Engl J Med 358 (2008) 1370-1380
46. Vakili B.A., Okin P.M., and Devereux R.B. Prognostic implications of left ventricular hypertrophy. Am Heart J 141 3 (2001) 334-341
47. Klapholz M., Maurer M., Lowe A.M., et al. Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol 43 8 (2004) 1432-1438
48. Vaziri S.M., Larson M.G., Lauer M.S., et al. Influence of blood pressure on left atrial size: the Framingham Heart Study. Hypertension 25 (1995) 1155-1160
49. Tarazi R.C., Miller A., Frohlich E.D., et al. Electrocardiographic changes reflecting left atrial abnormality in hypertension. Circulation 34 5 (1966) 818-822
50. Frohlich E.D., Tarazi R., and Dustan H.P. Clinical-physiological correlations in the development of hypertensive heart disease. Circulation 44 3 (1971) 446-455
51. Matsuda M., and Matsuda Y. Mechanism of left atrial enlargement related to ventricular diastolic impairment in hypertension. Clin Cardiol 19 (1996) 954-959
52. Pritchett A.M., Mahoney D.W., Jacobsen S.J., et al. Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol 45 (2005) 87-92
53. Safar M.E., Levy B.I., and Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 107 (2003) 2864-2869
54. Borlaug B.A., and Kass D.A. Ventricular-vascular interaction in heart failure. Heart Fail Clin 4 (2008) 23-36
55. Izzo J.L. Arterial stiffness and the systolic hypertension syndrome. Curr Opin Cardiol 19 (2004) 341-352
56. Borlaug B.A., Melenovsky V., Redfield M.M., et al. The impact of arterial load and loading sequence on left ventricular tissue velocities in humans. J Am Coll Cardiol 50 16 (2007) 1570-1577
57. Yamamoto K., Nishimura R.A., and Redfield M.M. Assessment of mean left atrial pressure from the left ventricular pressure tracing in patients with cardiomyopathies. Am J Cardiol 78 (1996) 107-110
58. Lester S.J., Tajik J., Nishimura R.A., et al. Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later. J Am Coll Cardiol 51 (2008) 679-689
59. Rossvoll O., and Hatle L.K. Pulmonary venous flow velocities recorded by transthoracic Doppler ultrasound: relation to left ventricular diastolic pressures. J Am Coll Cardiol 21 (1993) 1687-1696
60. Brun P., Tribouilloy C., Duval A.M., et al. Left ventricular flow propagation during early filling is related to wall relaxation: a color M-mode Doppler analysis. J Am Coll Cardiol 20 (1992) 420-432
61. Firstenberg M.S., Levine B.D., Garcia M.J., et al. Relationship of echocardiographic indices to pulmonary capillary wedge pressures in healthy volunteers. J Am Coll Cardiol 36 (2000) 1664-1669
62. Ho C.Y., and Solomon S.D. A clinician's guide to tissue Doppler imaging. Circulation 113 (2006) e396-e398
63. Nagueh S.F., Middleton K.J., Kopelen H.A., et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 30 (1997) 1527-1533
64. Ommen S.R., Nishimura R.A., Appleton C.P., et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study. Circulation 102 (2000) 1788-1794
65. Wang J., Khoury D.S., Thohan V., et al. Global diastolic strain rate for the assessment of left ventricular relaxation and filling pressures. Circulation 115 (2007) 1376-1383
66. McGuire D.K., Levine B.D., Williamson J.W., et al. A 30-year follow-up of the Dallas Bedrest and Training Study: II. Effect of age on cardiovascular adaptation to exercise training. Circulation 104 (2001) 1358-1366
67. Arbab-Zadeh A., Dijk E., Prasad A., et al. Effect of aging and physical activity on left ventricular compliance. Circulation 110 (2004) 1799-1805
68. Wachtell K., Bella J.N., Rokkedal J., et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Circulation 105 9 (2002) 1071-1076
69. Williams B., Lacy P.S., Thom S.M., et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 113 9 (2006) 1213-1225
70. Kostis J.B., Davis B.R., Cutler J., et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA 278 3 (1997) 212-216
71. Jamerson K., Weber M.A., Bakris G.L., et al. ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359 23 (2008) 2417-2428
72. Rg A., London G.M., O'Rourke M.F., et al. Improvement in blood pressure, arterial stiffness, and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patients: comparison with atenolol. Hypertension 38 (2001) 922-926
73. Brilla C.G., Funck R.C., and Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 102 (2000) 1388-1393
74. Devereux R.B., Dahlöf B., Gerdts E., et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) trial. Circulation 110 (2004) 1456-1462
75. Dzau V.J. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37 (2001) 1047-1052
76. Lonn E.M., Yusuf S., Jha P., et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90 (1994) 2056-2069
77. Lonn E., Shaikholeslami R., Yi Q., et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J Am Coll Cardiol 43 12 (2004) 2200-2206
78. Yusuf S., Sleight P., Pogue J., et al., The Heart Outcomes Prevention Evaluation Study investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
79. Wachtell K., Dahlöf B., Rokkedal J., et al. Change in left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Am Heart J 144 (2002) 1057-1064
80. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 362 9386 (2003) 777-781
81. Cleland J.G.F., Tendera M., Adamus J., et al., On behalf of PEP-CHF Investigators. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 27 (2006) 2338-2345
82. Massie B.M., Carson P.E., McMurray J.J., et al., The I-PRESERVE Investigators. Irbesartan in heart failure with preserved ejection fraction. N Engl J Med 359 23 (2008) 2456-2467
83. Davis B.R., Kostis J.B., Simpson L.M., et al. Heart failure with preserved and reduced left ventricular ejection fraction in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack trial. Circulation 118 (2008) 2259-2267
84. Aurigemma G.P., and Gaasch W.H. Clinical practice. Diastolic heart failure. N Engl J Med 351 11 (2004) 1097-1105
85. The J-ELAN Investigators. Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. Circ J 70 (2006) 124-128
86. Higashi M., et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res 93 (2003) 767-775
87. Zile M., Gaasch W., Little W., et al., MCC-135 GO1 Investigators. A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design. J Card Fail 10 (2004) 193-199